newsfilter
← Latest News
FDA Press Releases·

FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease

  • The U.S. FDA approved Infilbray (venglustat) tablets on November 18, 2026, as the first treatment for neurological symptoms of Type 3 Gaucher disease (GD3) in adults & pediatric patients weighing at least 15 kg.
  • Infilbray crosses the blood-brain barrier to reduce the accumulation of harmful glucosphingolipids in the brain & body.
  • GD3 is a rare inherited condition causing progressive neurological issues such as balance, coordination, speech, memory, & thinking difficulties due to enzyme deficiency.
  • Clinical trial data from 43 patients aged 12+ showed Infilbray improved combined measures of ataxia & cognitive function compared to enzyme replacement therapy over 52 weeks.
  • The most common side effects include gastrointestinal symptoms & mood changes, with serious risks including suicidal ideation, vision clouding in younger patients, & adverse fetal development during pregnancy.
  • Genzyme Corporation, a Sanofi Company, received the approval, which included Orphan Drug designation & Priority Review status.